Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ECONOMY

Financiado

Cerrado

Endothelial Cells an Overlooked Non hematopoietic cOmponent of tuMor immunitY

"Despite decades of research, cancer remains the second leading cause of death globally. Amongst all cancers, lung cancer is the deadliest in both men and women worldwide. Immune checkpoint blockade (ICB) recently emerged as promi... ver más

31/07/2023

VLAAMS INSTITUUT...

166K€

Presupuesto del proyecto: 166K€

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-07-31

MSCA-IF-2020: Individual Fellowships

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

VLAAMS INSTITUUT BIOTECHNOL...

166.32K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TESTIMONY Tumor Endothelial Cells Gatekeepers Of Anti Tumor Immunity 178K€ Cerrado

EXPAND IT EXPANDing Immune Cells and their Tumor Antigens during check... 3M€ Cerrado

UTILIUM Unraveling The Immune Landscape In Uveal Melanoma 200K€ Cerrado

TxImmuneOrganoids Divide and conquer using patient derived tumour organoids t... 225K€ Cerrado

TNT-TUMORS Therapeutic approaches to enhance innate immunity against Tu... 2M€ Cerrado

artFibro Artifying fibroblasts: Perturbation modelling in the lung tu... 2M€ Cerrado

Duración del proyecto: 27 meses Fecha Inicio: 2021-04-12
Fecha Fin: 2023-07-31

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 166K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Despite decades of research, cancer remains the second leading cause of death globally. Amongst all cancers, lung cancer is the deadliest in both men and women worldwide. Immune checkpoint blockade (ICB) recently emerged as promising cancer therapy. While extremely successful in hematopoietic cancers and melanoma, success in lung cancer is very limited. We are therefore in desperate need to devise novel treatment strategies. One approach would involve remodelling the lung cancer immune landscape to improve clinical response to ICB. A so far overlooked non-hematopoietic component of the immune system which potentially greatly contribute to tumor immunity are endothelial cells (ECs). Most intriguingly, tumor EC (TEC) subsets expressing diverse immune markers were identified, in parallel with the discovery of diverse metabolic phenotypes in TECs. The host lab identified TECs with transcriptional signatures related to antigen processing and presentation (MHCII+). However, the functional significance of MHCII+ TECs in tumor immunity and whether their immune-related functions could be regulated by underlying metabolic programming is unknown. Given the strategic ""first line"" location of TECs in the tissue, the question is whether, ICB’s effectiveness can be partly attributed to TEC immunity. I therefore propose to investigate the interactions between MHCII+ TECs and T cells and the effects of such interactions on tumor immunity using state-of-the-art inducible EC-specific MHCII knock-out mice. Moreover, I will assess metabolic signatures in immune-TECs and test potential metabolic regulation of TECs’ immune functions. Such metabolism-driven regulation could open new therapeutic possibilities, utilizing already available pharmaceutical inhibitors to remodel the tumor immune landscape in order to create a favourable context for immunotherapy. Thus, the proposed research is expected to pave the way for exciting new combination treatment strategies for lung cancer."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores